問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Psychiatry

更新時間：2023-09-19

陳高欽
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳高欽

List

18Cases

2005-06-02 - 2007-03-22

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-01-13 - 2022-06-07

Phase III

Completed
A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor

  • Condition/Disease

    Major Depressive Disorder

  • Test Drug

    ESKETAMINE

Participate Sites
10Sites

Recruiting10Sites

2018-03-01 - 2021-03-31

Phase III

Completed
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Paliperidone Palmitate

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

楊延光
National Taiwan University Hospital

Division of Psychiatry

白雅美
Taipei Veterans General Hospital

Division of Psychiatry

2005-01-01 - 2008-11-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-01-01 - 2014-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-10-01 - 2025-04-18

Phase III

Completed
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials (CONNEX-X)

  • Condition/Disease

    schizophrenia

  • Test Drug

    BI 425809

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

2015-01-29 - 2016-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-04-01 - 2024-12-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2021-05-31 - 2027-12-31

Phase II/III

Active
An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

  • Condition/Disease

    Refractory Schizophrenia

  • Test Drug

    錠劑

Participate Sites
5Sites

Recruiting5Sites

2007-12-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB